

QUARTERLY ACTIVITIES & CASHFLOW REPORT QUARTER ENDED 30 SEPTEMBER 2026

Investor Conference Call at 11.00am AEDT (8.00am AWST) on 26 October 2026

PERTH, Australia, 26 October 2026: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the real time, point of care assessment and management of coronary artery disease globally, is pleased to release its Appendix 4C – Quarterly Cashflow Report and Activities Update for the quarter ended 30 September 2026 (the **Quarter**). All financial results are in Australian dollars and are unaudited.

Highlights

- **Huntsville Hospital Health System, Artrya's largest customer to date, signs 5-year commercial agreement, becoming the first SAPPHIRE Study participant to convert to full commercial use**
- **U.S. commercial rollout continued to advance, with Northeast Georgia Health System starting to expand beyond its launch site and Cone Health progressing towards clinical deployment.**
- **Salix® Coronary Plaque utilisation increased materially following implementation of the pre-authorisation workflow at Tanner Health in mid-September, with the higher level of activity continuing into October.**
- **Substantial U.S. interest in the Salix® platform and Salix® Coronary Plaque, with SAPPHIRE participants and inbound health systems progressing commercial engagement based on the clinical, workflow and economic value of the platform.**
- **SAPPHIRE continued to support both clinical evidence generation and commercial engagement across participating U.S. health systems, with Huntsville providing the first conversion to a commercial customer.**
- **Expanding clinical evidence package to support a more comprehensive Salix® Coronary Flow 510(k) submission**
- **Artrya was included in the S&P/ASX 300 Index and strengthened its Board and executive leadership to support the next phase of commercial growth.**
- **Pro forma cash position of \$67.2M at 30 September 2026 – with an additional FY2026 R&D rebate claim of \$4.8M in process**

John Konstantopoulos, Co-Founder and CEO of Artrya commented:

“Commercial execution in the U.S. is our key priority, and we made significant progress during the Quarter. We signed our largest customer to date, Huntsville Hospital Health System, which also became the first SAPPHIRE study partner to convert to a long-term commercial agreement. Northeast Georgia Health System is expanding beyond its initial site, Cone Health continues to progress towards deployment, and we are seeing growing inbound interest from U.S. health systems.

Importantly, our commercial momentum is being driven by the value Salix® Coronary Anatomy and Salix® Coronary Plaque deliver today. At Tanner Health, the implementation of our pre-authorisation workflow in mid-September addressed a key reimbursement barrier to plaque assessment and was followed by a material increase in Salix® Coronary Plaque utilisation. That higher level of activity has continued into October. This unique workflow capability is built into Salix® and will be deployed as part of future customer implementations.

Our commercial focus is on bringing more health systems live to increase the number of CCTA studies processed through Salix®, while driving adoption of the reimbursed Salix® Coronary Plaque module across those customers. These priorities are designed to accelerate utilisation, customer conversion and revenue generation as we scale our U.S. commercial operations.

In terms of our technology pipeline, we continue to progress Salix® Coronary Flow as an additional module within the broader Salix® platform. In previous ASX releases, we expected the FDA submission to be imminent with FDA clearance anticipated by end 2026. Subsequent review of clinical study data identified inconsistencies in expert reader assessments

within a clinical sub-study and, together with recent regulatory outcomes in the sector, we have now decided to strengthen the evidence package and undertake an additional reader study before filing. We believe this is the appropriate approach to support a comprehensive submission and provide the strongest prospects of a successful regulatory outcome.”

U.S. COMMERCIAL EXECUTION

Huntsville Hospital Health System largest U.S. customer to date and first SAPHIRE commercial conversion

Post the end of the Quarter, Artrya converted its first SAPHIRE Study participant into a commercial customer, signing a five-year commercial agreement with Huntsville Hospital Health System (**HH Health**). The agreement is a significant milestone for Artrya and provides the first evidence of the Company's strategy to use SAPHIRE to build clinical experience and research relationships that can develop into revenue-generating commercial partnerships.

Under the five-year agreement with a minimum of US\$0.5M, HH Health will license Salix® Coronary Anatomy on a subscription basis, with usage of Salix® Coronary Plaque, and Salix® Coronary Flow (once cleared) generating additional fees per scan.

HH Health is Artrya's largest customer to date and materially expands the Company's addressable scan volumes and revenue opportunity moving forward. The network spans 15 hospitals across Alabama and Tennessee and 19 heart centres, with more than 1,000 cardiac staff and 58 cardiologists. It conducts approximately 60,000 non-invasive cardiology tests annually.

Planning for the integration of Salix® into HH Health across the full network is now underway and is a key priority. This collaborative work will start with integration with the HH Health clinical PACS and I.T. systems, followed by workflow training and reimbursement pathways, and is well supported by Artrya's on the ground Customer Success Team.

Artrya will continue to build on this first SAPHIRE conversion through ongoing commercial engagement with the other participating high-volume health systems, while continuing to mature the broader pipeline of inbound opportunities from U.S. health systems.

Foundation customer rollout moving from deployment to utilisation


At Tanner Health, Artrya's first U.S. customer, CCTA scan volumes processed through Salix® Coronary Anatomy increased during the Quarter as the platform became embedded in clinical workflow.

A key focus during the Quarter was increasing adoption of Salix® Coronary Plaque. In mid-September, Artrya implemented a pre-authorisation workflow within Salix® designed to address a key reimbursement barrier to plaque utilisation. The workflow enables clinicians to identify, in near real time, whether the relevant insurance pathway supports reimbursement for plaque assessment before ordering the module. This reduces reimbursement uncertainty for the health system and simplifies the workflow for clinicians.

Following implementation, Tanner Health recorded a material increase in plaque assessments during September, with the higher level of activity continuing into October. While still early, the initial response supports the role of reimbursement workflow integration in driving adoption of fee-per-scan modules. The capability can be incorporated into future Salix® customer deployments.


Salix® Coronary anatomy exam volume growth over the past 4 quarters

The chart below illustrates the directional growth in Salix® Coronary Anatomy exams across the U.S. customer base over the past four quarters. Absolute volumes are not disclosed at this early stage of commercial rollout.



Salix® Coronary plaque exam volume growth over the past 4 quarters

The chart below illustrates the directional change in Salix® Coronary Plaque exams over the past four quarters, including the increase in the September quarter following implementation of the pre-authorisation workflow.



At Northeast Georgia Health System (**NGHS**), Salix® Coronary Anatomy was deployed at the main campus at the beginning of the Quarter, which accounts for the majority of scan volumes across their network. Rollout to the remaining NGHS sites

is well advanced. This will establish the platform across the broader NGHS network, supporting increased utilisation and further growth in scan volumes and fee-per-scan revenues.

At Cone Health, Artrya continues to work closely with the health system's clinical and IT teams to progress implementation towards completion. These activities were initially slowed by the transition of Cone Health into Kaiser Permanente, but Cone Health have reconfirmed that implementation of Salix® remains a key near term priority.

With Tanner Health fully integrated and implementation progressing across NGHS, Cone Health and HH Health, the commercial focus is increasingly shifting from initial deployment towards driving utilisation and growing recurring commercial revenues across the installed base.

SAPPHIRE supporting clinical evidence and commercial expansion

Artrya continued to progress the SAPPHIRE Study during the Quarter, with participating U.S. health systems gaining early experience with the Salix® platform. The Customer Support Team focused on integrating Salix® and training principal investigators and their research teams, with Artrya management visiting many SAPPHIRE sites in September to engage with investigators and commercial teams.

SAPPHIRE continues to progress in close collaboration with study partners, both clinically and commercially. Importantly, commercial engagement with SAPPHIRE participants continues independently of the Study timetable, as demonstrated by Huntsville becoming the first SAPPHIRE participant to convert to a commercial customer.

SAPPHIRE remains an important part of Artrya's strategy, enabling participating health systems to evaluate Salix® within their clinical workflows while generating evidence to support broader adoption.

Artrya strengthens evidence package for Salix® Coronary Flow 510(k) submission

Artrya continued preparations for its Salix® Coronary Flow 510(k) submission to the U.S. Food and Drug Administration (FDA) during the Quarter. Coronary Flow is expected to expand the Salix® product suite, integrating with FDA-cleared Salix® Coronary Anatomy and Salix® Coronary Plaque to enable an integrated Anatomy-Plaque-Flow assessment from a single CT scan. Once cleared, Salix® Coronary Flow assessments will qualify for reimbursement under an existing Category I CPT code.

In recent ASX releases, the Salix® Coronary Flow FDA submission was described as imminent with FDA clearance by end of 2026, reflecting the Company's expectation at that time. Subsequent review of clinical study data identified inconsistencies in expert reader assessments within a clinical sub-study. Taking this into account, together with recent regulatory outcomes in the sector, Artrya has now determined that the submission would benefit from additional clinical evidence and elected to undertake an additional reader study to strengthen the evidence package supporting the submission.

The additional reader study was not requested by the FDA but is a prudent step intended to support a comprehensive, high-quality submission and address potential clinical evidence requirements upfront. As a result of this additional work, the previously anticipated submission timing has been extended. Artrya will update the market when the Salix® Coronary Flow 510(k) submission is lodged with the FDA and cleared by the FDA.

Salix® Coronary Flow is one of a number of modules that can expand the clinical and commercial opportunity of the broader Salix® platform. Over time, Artrya intends to extend the platform into additional areas of cardiac assessment, further increasing the value Salix® can deliver to health systems through a single integrated platform.

FINANCIAL & CORPORATE MATTERS

Operating Cashflows for the Quarter & Cash position

During the Quarter, the Company's cashflows from operating activities included:

- **Customer receipts** of \$84,000 related to receipt of:
 - subscription revenues from the first two live commercial customers; and
 - per-scan revenues from Tanner Health. The Salix® plaque volumes increased considerably in September following the pre-authorisation upgrade to the Salix® platform in mid-September, and we are seeing increased volumes continue in October.
- **Operating costs** (excluding R&D rebate and interest income) were \$7.4M, up from \$6.5M in the prior quarter, with the key items for this Quarter as follows:
 - Staff costs increased by \$0.7M to \$3.6M in line with increased commercialisation activities, headcount increases in Australia and the U.S., as well as FY2027 annual pay increases;
 - Advertising & Marketing also increased by \$0.2M to \$0.4M as commercial activities and customer engagement continued to ramp up;
 - R&D expenditure reduced by \$0.3M to \$0.8M.
- **Interest income** of \$0.5M from the \$30M held in a six-month term deposit;
- **Related party payments** of \$0.3M for fees and salaries paid to Directors and their related entities.

Financing cashflows for the Quarter were nil and there was a nominal investment in plant and equipment. In total, the Company had Total Net Cash Outflows for the Quarter of \$6.9M.

The Company will lodge its claim for the FY2026 R&D rebate this month, based on complying activities during FY2026, and estimates to receive a \$4.8M cash rebate in early 2027.

The Company holds a \$30.0M six-month bank term deposit as part of treasury management activities. This term deposit is classified as a financial asset under AASB 9 and is not considered cash or cash equivalents for the purposes of the Appendix 4C. The investment is readily realisable but does not meet the definition of cash equivalents due to its maturity exceeding three months.

The Company held \$67.2M of cash and term deposits at 30 September 2026.

Corporate Matters - Strengthened Leadership and Governance

During the Quarter, Artrya appointed Helen Kurincic as a Non-Executive Director, strengthening the Board's healthcare, imaging and capital markets expertise. Ms Kurincic brings more than 30 years of leadership experience across radiology, healthcare, specialist medicine and financial markets. She currently serves as Chair of McMillan Shakespeare and Non-Executive Director of Ramsay Health Care, having previously chaired Integral Diagnostics.

During the Quarter, Clayton Hatch commenced as Chief Financial Officer, as previously announced.

Following Artrya's inclusion in the S&P/ASX 300 Index, the Board has established an Audit and Risk Committee and a Remuneration and Nominations Committee, to further strengthen the Company's governance framework.

Investor engagement

Market engagement was ongoing during the Quarter, with Artrya presenting at the Bioshares Conference in Queenstown, New Zealand in August, and CEO John Konstantopoulos and CFO Clayton Hatch participated in non-deal roadshow meetings following the release of FY2026 Results. Post the Quarter, Artrya presented at the Canaccord Genuity Drug & Device Conference in Noosa. Ord Minnett have also now initiated research coverage.

Quarterly Investor Webinar

The Company's Co-Founder and CEO John Konstantopoulos, will host a Quarterly Investor Webinar at **11.00am AEDT (8.00am AWST)** on **26 October 2026**. A recording of the webinar will be available on the Investor Centre section of the Company's website. Shareholders will also have an opportunity to participate in a Q&A session at the end of the briefing.

Date: **26 October 2026**

Time: **11.00am AEDT / 8.00am AWST**

To pre-register for this conference, please use the following link below:

https://artrya.zoom.us/webinar/register/WN_1RcR0MuhST64dA960bfxzg

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

For more information:

Corporate Enquiries

John Konstantopoulos
Co-Founder and Chief Executive Officer
Tel: +61 8 6478 7816
Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger
Hawkesbury Partners
Tel: +61 499 100 038 or +61 410 577 155
Email: investors@artrya.com

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates and Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya's business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Artrya Limited

ABN

53 624 005 741

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	84	84
1.2 Payments for		
(a) research and development	(784)	(784)
(b) product manufacturing and operating costs	(1,625)	(1,625)
(c) advertising and marketing	(370)	(370)
(d) leased assets	(101)	(101)
(e) staff costs	(3,594)	(3,594)
(f) administration and corporate costs	(942)	(942)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	510	510
1.5 Interest and other costs of finance paid	(2)	(2)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(6,824)	(6,824)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(20)	(20)
(d) investments (term deposit)	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(20)	(20)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other	-	-
3.10	Net cash from / (used in) financing activities	-	-

4.	Net increase / (decrease) in cash and cash equivalents for the period		
		44,025	44,025
4.1	Cash and cash equivalents at beginning of period		
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(6,824)	(6,824)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(20)	(20)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	(12)	(12)
4.6	Cash and cash equivalents at end of period	37,169	37,169

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	37,169	44,025
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	37,169	44,025

*** The Company has invested \$30 million of its cash reserves into a short-term, six month bank deposit as part of treasury management activities. This term deposit is classified as a financial asset under AASB 9 and is not considered cash or cash equivalents for the purposes of this Appendix 4C. Accordingly, the investment is excluded from cash and cash equivalents at quarter end. The investment is readily realisable but does not meet the definition of cash equivalents due to its original maturity exceeding three months.**

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	276
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (see table 7.6 below)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	n/a		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(6,824)
8.2	Cash and cash equivalents at quarter end (item 4.6)	37,169
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	37,169
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1) * The Company has available investment funds held in a short-term, six-month bank term deposit of \$30 million that is excluded from cash and cash equivalents at the quarter end. The investment is readily realisable but does not meet the definition of cash equivalents due to its original maturity exceeding three months. When this \$30 million is included, there are 9.84 quarters of funding available.	5.45*
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: **26 October 2026**

Authorised by: **Board of Directors, Artrya Limited**

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.